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Abstract 
Background.  Pain is the most common presenting somatic symptom in medical outpatients, 
and depression and anxiety are the two most common mental disorders. They frequently co-
occur, are under-treated, and result in substantial disability and reduced health-related quality of 
life. 
Objectives.  The Comprehensive vs. Assisted Management of Mood and Pain Symptoms 
(CAMMPS) study is a randomized comparative effectiveness trial designed to test the relative 
effectiveness of a lower-resource vs. a higher-resource technology-assisted intervention for the 
management of patients suffering from pain plus anxiety and/or depression.   
Methods/Design. CAMMPS has enrolled 294 primary care patients with chronic pain plus 
comorbid anxiety and/or depression and randomized them to either:  1) Assisted Symptom 
Management (ASM) consisting of automated symptom monitoring by interactive voice recording 
or Internet and prompted pain and mood self-management; or 2) Comprehensive Symptom 
Management (CSM) which combines ASM with optimized medication management delivered by 
a nurse-physician specialist team and facilitated mental health care. Outcomes are assessed at 
baseline, 1, 3, 6, and 12 months. The primary outcome is a composite pain-anxiety-depression 
(PAD) severity score. Secondary outcomes include individual pain, anxiety, and depression 
scores, health-related quality of life, disability, healthcare utilization, and treatment satisfaction.  
Discussion. CAMMPS provides an integrated approach to PAD symptoms rather than 
fragmented care of s ingle symptoms; coordinated symptom management in partnership with 
primary care clinicians and psychologists embedded in primary care; efficient use of health 
information technology; attention to physical and psychological symptom comorbidity; and the 
coupling of self-management with optimized medication management and facilitated mental 
health care.  
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1. Introduction 
 Pain is the most common symptom reported in both the general population and in 
primary care [1].  Pain complaints account for more than 40% of all symptom-related 
outpatient vis its and over 100 million ambulatory encounters in the U.S. each year [2]. In the 
United States alone, chronic pain conditions cost more than $500 billion annually in direct 
medical costs and lost productivity [1]. Pain medications are the second most prescribed 
class of drugs (after cardiac-renal drugs), accounting for 12% of all medication prescribed 
during ambulatory office vis its in the United States [3]. Indeed, persistent pain is a major 
international health problem, prompting the World Health Organization to endorse a global 
campaign against pain [4].  
 Musculoskeletal pain is consistently the most common, disabling, and costly of all 
pain complaints [5]. Indeed, two-thirds of pain-related outpatient vis its are due to 
musculoskeletal pain, accounting for nearly 70 million outpatient vis its in the U.S. each year 
[2]. In a study assessing pain as the 5 th vital s ign in 9 Veteran Administration (VA) clinics, 
more than 80% of all pain complaints expressed by Veterans were musculoskeletal in nature 
[6]. Two Institute of Medicine reports have summarized the enormous functional and 
economic impact of musculoskeletal pain on both the working and the retired population [1, 
7]. 
 Depression and anxiety are the two most common mental health problems seen in 
the general medical setting, each being present in 10%-15% of primary care patients [8-10]. 
They produce substantial disability and decrements in health-related quality of life, often 
exceeding the impairment seen in patients with chronic medical disorders [11, 12]. 
Additionally, depression and anxiety each result in substantial health care costs as well as 
indirect costs due to lost work productivity [13, 14].   
 Pain, anxiety, and depression are often inextricably linked (i.e., the PAD triad), such 
that disentanglement is scientifically and clinically impractical [15-17]. Moreover, PAD 
symptoms have reciprocal negative effects on treatment response of one another, and 
additive adverse effects on health outcomes [18-20]. Thus, interventions that target the PAD 
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symptoms collectively rather than individually are desirable. Also, s ince most patients with 
PAD symptoms are treated predominantly or exclusively in primary care, PAD interventions 
that are collaborative with or integrated into primary care are likely to have the greatest 
impact [10].  
 Comprehensive vs. Assisted Management of Mood and Pain Symptoms (CAMMPS) 
is a randomized comparative effectiveness trial comparing two pragmatic interventions (an 
intensive vs. a low-resource approach) for treating the pain plus anxiety and/or depression. 
The assisted symptom management arm (ASM) intervention consists of automated symptom 
monitoring and prompted pain and mood self-management. The comprehensive symptom 
management (CSM) intervention combines ASM with optimized medication management 
and facilitated mental health care by a centralized nurse-physician team. The primary aim is 
to compare the 12-month effectiveness of CSM vs. ASM in improving overall pain and mental 
health. Secondary outcomes will include health-related quality of life, disability, health care 
utilization, and treatment satisfaction. 
2. Methods 
2.1. Overview of Study Design and Research Aims and Hypotheses 
 CAMMPS is a 12-month randomized comparative effectiveness trial comparing a low-
resource entirely automated intervention to a more intense comprehensive intervention that 
complements the automated intervention with a nurse-physician team collaborating with the 
primary care team through a largely telecare approach (i.e., most communication with 
patients and providers is by telephone or through secure e-mails and websites). Outcomes 
are assessed at 1, 3, 6, and 12 months. The study was carried out in accordance with The 
Code of Ethics of the World Medical Association (Declaration of Helsinki). CAMMPS has 
been reviewed and approved by the Indiana University Institutional Review Board and the VA 
Research Review Committee. 
 CAMMPS has one primary aim, two secondary aims, and one exploratory aim. 
Aim 1.  To compare 12-month effectiveness of CSM vs. ASM in improving overall pain and 
mental health. Our hypothesis is that CSM will be superior to ASM in reducing a composite 
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pain-anxiety-depression score. 
Aim 2.  To compare 12-month effectiveness of CSM vs. ASM in improving specific PAD 
symptoms. Our hypothesis is that CSM will be superior to ASM in reducing individual pain, 
anxiety, and depression scores.  
Aim 3. To compare the effects of CSM vs. ASM on secondary outcomes, including health-
related quality of life, disability, treatment satisfaction, and health care utilization. 
Aim 4. To explore patient-perceived barriers and facilitators of the CAMMPS intervention and 
the relative contribution of each intervention component to overall symptom improvement.  
2.2.  Conceptual Model 
  Figure 1 depicts the conceptual model underlying the CAMMPS trial. The ASM arm 
has 2 components that enhance usual care:  automated PAD symptom monitoring and 
automated prompting of the patient to use pain and mood self-management strategies. The 
CSM arm adds 3 additional components to ASM:  nurse contacts; optimized medication 
regimens for PAD symptoms; and facilitated mental health care.  Collectively, these 5 
components constitute the active intervention ingredients which may lead to an improvement 
in the primary (proximal) outcome, namely symptom burden as measured by the composite 
PAD symptom score. Secondary (distal) outcomes postulated to benefit from reduced PAD 
symptom burden include health-related quality of life (HRQoL), disability, patient satisfaction, 
and health care utilization. 
2.3. Eligibility 
  The study population consists of Veterans 18 years and older receiving care from one 
of 5 primary care clinics at a large VA Medical Center in the Midwest. Patients are eligible if 
they have pain plus psychiatric comorbidity. 
 Pain must meet all of the 3 following criteria:  (1) musculoskeletal, either localized (in 
the arms, legs, back, or neck) or widespread (fibromyalgia); (2) persistent for 3 months or 
longer [21, 22] despite a trial of at least one analgesic medication; (3) at least moderate in 
severity, defined as a Brief Pain Inventory average severity score of 5 or greater in the past 
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week [23] or having at least moderately interfered with work or other activities in the past 
month.  
 Psychiatric comorbidity must meet any 1 of the following 3 criteria. 
 (1)  Depression must be of at least moderate severity, defined as a PHQ-8 score of 
10 or greater with either depressed mood and/or anhedonia being endorsed.  In previous 
studies, more than 90% of patients fulfilling this PHQ-8 criterion had major depression and/or 
dysthymia, and the remaining patients had clinically s ignificant depression with substantial 
functional impairment [24, 25].  
 (2)  Anxiety must be of at least moderate severity, defined as a GAD-7 score of 10 or 
greater. In previous studies, the majority of patients fulfilling this GAD-7 criterion had one or 
more common DSM-IV anxiety disorders (generalized anxiety, panic, social anxiety, and/or 
posttraumatic stress disorder), and the remaining patients had clinically s ignificant anxiety 
with substantial functional impairment [26, 27]. While the area under the curve is highest for 
generalized anxiety disorder (.91), it is also good for panic disorder (.85), social anxiety 
disorder (.83), and PTSD (.83). The positive likelihood ratio for a GAD-7 cutpoint of ≥ 10 for 
these 4 disorders is 5.1, 2.9, 3.6, and 3.5, respectively. 
 (3) Mixed anxiety-depression is defined as combined PHQ-8 and GAD-7 score ≥ 12.  
Scores of 6 or higher on each scale represent at least mild depression or anxiety symptoms, 
respectively [26], and this level of symptoms has been shown responsive to treatment [28]. 
 Excluded are individuals who: (a) do not speak English; (b) have moderately severe 
cognitive impairment as defined by a validated 6-item cognitive screener [29]; (c) have 
schizophrenia, bipolar disorder or other psychosis; (d) have a severe or complex mental 
illness or exhibit suicidal thoughts as their condition is unsuitable for a predominantly telecare 
intervention; (e) are pregnant; (f) have an anticipated life expectancy of less than 12 months.   
2.4.  Recruitment and Randomization 
 Physicians working in the 5 primary care clinics were informed of the study in detail 
and were asked for permission to contact their patients for possible participation in the study. 
Since this trial is a collaborative care intervention, only patients whose physicians provided 
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consent were enrolled. Electronic medical records are used to create a master list of 
individuals who, within the preceding 36 months, have received an ICD diagnosis of 
musculoskeletal pain condition and either a depressive or anxiety disorder. This patient list 
was updated quarterly during the enrollment period. A letter briefly describing CAMMPS that 
included a 2-item pain severity and interference scale was mailed to patients on this list who 
could either contact the study coordinator or return a form indicating their interest in the study 
eligibility interview. Individuals indicating interest and screening positive for moderate pain 
severity or interference were contacted by phone and assessed for study eligibility.  Eligible 
patients who were interested in participating were scheduled for an initial study vis it where, 
after providing written informed consent, underwent a baseline study interview conducted by 
a research assistant.  
 Participants then met with a project coordinator who performed the randomization to 
keep the two research assistants responsible for outcome assessments blinded to treatment 
arm assignment. Allocation to treatment arm was carried out by a computer-generated 
randomization list with randomly varying block s izes of 4 and 8 to maximize allocation 
concealment.  Study participants are reimbursed $25 for each of the study interviews 
completed (baseline and 4 follow-up interviews) and continue to receive all their standard VA 
medical care. 
2.5.  Data Collection Protocol 
 Table 1 outlines the data collection protocol, including the variables that are 
measured, number of items, internal reliability (Cronbach’s coefficient alpha) for scales, and 
time points for assessment. All assessments are conducted by a research assistant blinded 
to study group. 
2.5.1. Primary outcome measure 
  The primary outcome measure is the composite z-score of the main pain, anxiety and 
depression scales in this trial: the BPI, GAD-7, and PHQ-9, respectively. These 3 symptom 
scales total 27 items: 11 items for pain, 7 for anxiety, and 9 for depression. Each of these 
measures has proven sensitive to change in treatment trials [30-32]. The composite z-score 
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reflects the 3 symptoms being targeted for treatment in CAMMPS and provides a 
standardized primary outcome that could not be derived from 3 disparate symptom 
measures. 
 As an important secondary outcome, a composite pain-anxiety-depression score from 
the PROMIS measures (www.healthmeasures.net) will be calculated, using the 8 item scales 
for depression and anxiety and pain from the PROMIS-57 Profile [33]. Conversion tables 
allow direct conversion of simple summed raw scores from PROMIS symptom scales into T-
score values. T-Score distributions are standardized such that a score of 50 represents the 
average (mean) for the US general population, and the standard deviation around that mean 
is 10 points. A high score represents greater symptom severity. For example, a person who 
has a T-score of 60 is one standard deviation worse than the general population for the 
symptom being measured. The composite PROMIS score will be the mean of the 3 symptom 
scores; thus, a patient with PROMIS pain, anxiety and depression scores of 66, 58, and 53 
would have a composite score of 59.  
2.5.2. Other measures 
  Clinical response is assessed for pain and mood using a 7-item patient-rated global 
change scale (much better, moderately better, a little better, same, a little worse, moderately 
worse, much worse) [34]. Three secondary anxiety measures include the PTSD Checklist 
(PCL) to assess the presence and severity of posttraumatic disorder [35]; the Hopkins 
Symptom Checklist 10-item anxiety scale [36]; and the Mini-SPIN 3-item screener for social 
anxiety disorder [37]. Two measures of somatization include the Patient Health 
Questionnaire 15-item somatic symptom scale (excluding the sexual problem item) [26] and 
the 8-item Somatic Symptom Scale [38].  Health-related quality of life is assessed with the 
Medical Outcomes Study Short-Form 12-item scale from which a Physical Component 
Summary score and Mental Component Summary score can be derived [39]; additionally, 8 
items from the SF-36 were included which, along with items from the SF-12, provide the full 
SF-36 social functioning, bodily pain, vitality and mental health scales [40]. Patient-rated 
disability is  assessed with the 3-item Sheehan Disability Scale [41] and a 2-item measure 
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that asks about the number of days in the past 4 weeks that the individual had to reduce 
activities by 50% or more for health-related reasons as well as percent effectiveness at work 
[23]. Additional scales include the 6-item pain catastrophizing scale from the Coping 
Strategies Questionnaire [42]; the 5-item REMIT scale which has shown to be useful in 
predicting depression remission [43]; and the PROMIS 4-item scales for fatigue and sleep 
problems [44], two symptoms that frequently co-occur with pain, anxiety and depression. 
 Medical comorbidity is assessed with a validated 9-disease checklist [45]. Substance 
use is assessed with the AUDIT-C for alcohol [46] as well as questions about the use of 
tobacco, illicit drugs, and family history [23]. Health care utilization (outpatient vis its, 
emergency department vis its, and hospitalizations) and treatments (medications and 
nonpharmacological treatments specific to pain and mental health) are assessed using an 
interview coupled with electronic medical review (EMR). Satisfaction with pain and mood 
treatments as well as the automated and nurse care manager components of the 
interventions are assessed with items used in previous trials [23, 25]. Three diagnostic 
variables were created:  probable major depressive disorder using the PHQ-9 diagnostic 
algorithm [26]; probable PTSD using a PTSD Checklist (PCL) score ≥ 41 [47]; and substance 
use risk derived from 13 items and categorized as low, intermediate, and high risk [23]. 
2.6. Assisted Symptom Management (ASM) Intervention 
 ASM has 2 principal components:  automated symptom monitoring and prompted 
pain and mood self-management.  Study participants complete regular symptom surveys 
either by interactive voice recorded (IVR) telephone calls or Internet (based upon patient 
preference); both IVR and internet approaches use push-technology (automated calls or e-
mail reminders) to optimize patient outreach. The schedule is weekly for the first month, 
twice a month for months 2-6, and monthly for months 7-12. This “tapering dose” of 
automated monitoring corresponds to the acute phase of initial treatment and dose 
adjustment or adding/switching medications, followed by less frequent monitoring during the 
relapse prevention phase. Since all patients have threshold levels of pain as well as 
depression and/or anxiety, more up-front intensive monitoring with initiation and adjustment 
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of symptom therapy followed by a tapering schedule is both rational and evidence-based [28, 
48]. The core survey includes 15 items:  a) brief pain (PEG), anxiety (GAD-2) and depression 
(PHQ-2) measures [26, 30]; b) items on sleep, fatigue, and irritability; c) items about global 
change (better, same, worse), and the degree to which symptoms have interfered with daily 
activities; and d) 3 items to prompt use of the pain and mood self-management units.  
 The Pain and Mood Self-Management Program includes approximately 12 hours of 
web-based instruction divided into 9 units (coping with pain; pain medications; 
communicating with providers; depression; anxiety; s leep; anger management; cognitive 
strategies; and problem-solving). For participants without Internet access, binders with the 
program materials were provided. These topics are partly derived from the nurse-
administered self-management program in previous trials [49, 50] and link to several public 
domain VA and non-VA websites with interactive self-management programs. Subjects are 
instructed in how to use the program by the nurse (CSM group) or project coordinator (ASM 
group). The web-based delivery of the program coupled with automated reminders to 
proceed through the 9 units is intended to enhance completion of the program.   
2.7. Comprehensive Symptom Management (CSM) Intervention 
2.7.1. CSM Structure and Overview 
  This arm couples telecare management by a nurse-physician team with ASM, thus 
testing “combined” therapy vs. “monotherapy” (ASM only). As illustrated in our conceptual 
model (Figure 1), the nurse provides several active components beyond ASM, including 
optimized medication management (analgesics and psychotropics) in conjunction with the 
supervising physician, facilitated mental health care, and enhanced education, motivation, 
and coordination of care through periodic telephone contacts. CSM is intentionally tailored to 
each patient’s specific PAD symptoms, treatment preferences, and response to therapy; 
thus, frequency of nurse contacts as well as the specific content of nurse calls will 
necessarily vary with a “treat to target” approach [10].   
  The nurse has scheduled telephone contacts with the patient at baseline, 1, 4, and 
12 weeks, as well as symptom-triggered contacts based upon automated monitoring trend 
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reports. The nurse monitors trend reports weekly, responds to automated monitoring clinical 
alerts and patient calls daily, and serves as the coordinating linchpin between patient, 
supervising physician symptom specialist, primary care physician, and psychologist or other 
mental health specialist. The nurse has weekly case management sessions with the 
supervising physician symptom specialist to review all new patients randomized to the CSM 
group to decide on a treatment plan, as well as to discuss enrolled patients not responding to 
therapy.  
2.7.2. Augmented Automated Symptom Monitoring for the CSM Arm    
 All patients randomized to the CSM arm receive the core ASM as described in section 
2.6 above.  However, ASM is enhanced in four ways for patients in the CSM arm to take 
advantage of the “technology-human” partnership provided by the centralized nurse care 
manager-physician team.  First, the 15-item core ASM survey is  augmented by 5 additional 
items:  medication adherence, side effects, desire for treatment changes, and request for a 
nurse care manager call. Second, patients can leave a recorded message for the nurse who 
in turn can leave recorded messages for patients. Third, ASM responses are tabulated in a 
trend report on a secure website. Trend reports are reviewed weekly by the nurse care 
manager. Fourth, e-mail alerts are sent to the nurse to trigger patient calls for medication 
s ide effects, patient requests for treatment change or a nurse call, or missed ASM reports.  
2.7.3. Facilitated Mental Health Care 
 Figure 2 summarizes the options for facilitated mental health care. Patients are 
offered an option of psychotropic medications, referral to a psychologist embedded in 
primary care for psychotherapeutic treatment, or combined therapy. Those who prefer 
medication are offered a referral to psychiatry, but those who refuse referral have the option 
of a psychotropic prescription from their primary care physician. Those with PTSD are 
especially encouraged to accept a mental health referral. Moreover, patients not responding 
to one treatment are encouraged to consider combined therapy and/or mental health referral. 
Depression (PHQ-9) and anxiety (GAD-7) scores that are obtained by the nurse in response 
to elevated mood scores derived from automated symptom monitoring are provided to the 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Page 13 of  36 
 
13 
 
treating psychologist as one metric of treatment response to determine if additional treatment 
sessions or modifications to treatment may be warranted.  
2.7.4 Optimized Pharmacotherapy 
  The nurse care manager obtains a detailed history of current and past analgesic 
and psychotropic use as well as patient-recalled effectiveness and tolerability. Based upon 
this, the nurse-physician team develops an initial treatment plan based upon evidence-based 
medication algorithms used in previous trials [28, 48, 51]. The stepped care analgesic 
algorithm includes: 1) acetaminophen or a nonsteroidal anti-inflammatory drug; 2) tricyclic 
antidepressants (amitriptyline, nortriptyline); 3) muscle relaxants (cyclobenzaprine, 
methacarbamol, tizanidine), gabapentinoids (gabapentin, pregabalin), or serotonin-
norepinephrine reuptake inhibitors [SNRI] (duloxetine, venlafaxine).  Topical analgesics 
(diclofenac cream, capsaicin, lidocaine) can be considered for areas of localized pain.  
Controlled analgesics (tramadol or opioids) are not discontinued for patients taking them on 
study enrollment but are not part of the analgesic algorithm for this trial.  
 Psychotropic medication is prescribed either by a mental health specialist or the 
primary care physician depending upon patient preferences (Figure 2). Due to their efficacy 
for both depression and anxiety, antidepressants are typically the preferred initial medication. 
These typically are either a selective serotonin reuptake inhibitor (SSRI), an SNRI, 
bupropion, or mirtazapine.  Patients referred to psychiatry for more complex disorders 
(including PTSD) might receive a broader array of psychotropics based upon type of disorder 
and treatment response. 
2.7.5. Duration of Intervention 
 This 12-month study is divided into 2 phases:  (1) acute phase (first 6 months) during 
which automated symptom monitoring occurs weekly for the first month and then every other 
week during months 2 through 6 to allow careful follow-up of symptoms and treatment 
adjustments; (2) continuation phase (last 6 months) during which automated symptom 
monitoring occurs once a month to allow further treatment adjustments in subjects who fail to 
achieve target clinical responses during the acute phase or to detect relapse in subjects who 
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do achieve target responses. Automated symptom monitoring allows nurse care manager 
contacts to be selective, thereby making 12-month surveillance more efficient.[52] 
2.7.6. Determining Treatment Changes 
 The algorithm for determining treatment changes (Figure 3) is  based upon 3 criteria: 
1) symptom severity of pain, anxiety and depression as assessed by the PEG, GAD-2, and 
PHQ-2 scores recorded in the ASM reports; 2) global rating of change which, if the patient 
reports improvement, is further categorized as a little better, moderately better, or a lot better; 
3) patient response to the question – “Would you like to make some changes in the treatment 
for your pain [mood]”. These 3 criteria assess the core outcome domains recommended by 
IMMPACT: symptom intensity/interference, patient-rated global improvement; and 
satisfaction with treatment [34, 53]. A ≥ 30% reduction in pain is a commonly accepted 
threshold in pain treatment trials and is therefore defined as a partial response (Criterion 1). 
Criterion 2 represents the patient’s assessment of the direction and magnitude of symptom 
change.  A patient’s desire for treatment change (Criterion 3) typically represents a clinical 
action threshold signifying dissatisfaction with the current level of symptom control and a 
willingness to embrace the costs of and adjustment to increased or added treatments. 
 The decision to make treatment changes in symptom-based conditions like pain, 
anxiety, and depression cannot be done in a formulaic (“cookbook”) fashion because, unlike 
conditions measured independent of patient-report (e.g., blood pressure, serum glucose, 
cholesterol), symptoms are self-rated and rely primarily on the patient’s internal weighting of 
symptom severity, interference with valued roles and activities, pros and cons of treatment 
changes, and other factors unique to the patient.  However, the 3 clinical response criteria 
are regularly assessed and applied by the nurse-MD symptom team in their weekly case 
management meetings. Clinical decision making is guided by the algorithm in Figure 3.  
2.8. Statistical considerations 
2.8.1. Sample size determination.   
 Sample size is determined to ensure adequate power for our primary hypothesis that 
CSM is superior to ASM in reducing composite PAD symptom severity. In our previous trials 
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targeting depression and pain in primary care and cancer patients, respectively, the average 
intervention effect s ize, compared to a usual care control group, was 0.55 for pain and 0.54 
for depression [48, 49]. Since CAMMPS is comparing CSM to an active comparator ASM 
group rather than a usual care control group, we estimate a smaller effect s ize of 0.35, which 
is half way between a small (0.2) and moderate (0.5) effect s ize [54].  The primary outcome 
will be a composite pain-anxiety-depression score using the BPI, GAD-7, and PHQ-9 scores, 
respectively. A standard z-score will be calculated as the scale score minus the sample 
mean divided by the sample standard deviation [55]. A composite pain-anxiety-depression 
score will be the average of the standard z-scores for the 3 scales. Since the z-score already 
is equal to the number of standard deviations, a between-group composite z-score difference 
of 0.35 is equivalent to an effect s ize of 0.35. Having 128 participants per treatment arm 
provides 80% power to detect a between-group effect s ize difference of 0.35 using a two-
sample t-test with a 5% Type I error rate. Allowing for 15% attrition in our present trial, we 
initially projected a need for 150 per treatment arm, or a total of 300 participants. Two-thirds 
of the way through enrollment, the attrition was less than 10%, indicating that a sample size 
of 286 would be sufficient. 
2.8.2. Statistical analyses 
 All analyses will be based on intention-to-treat in all randomized participants. As the 
main test of our trial’s treatment effect, we will evaluate the overall between-group 
differences on the composite pain-anxiety-depression z-score over the 12-month period of 
the trial using mixed effects model repeated measures (MMRM) analysis [48, 49]. 
Specifically, the composite z-score at 1, 3, 6, and 12 months will be used as the dependent 
variable in the model. Intervention group and dummy variables indicating the follow up time 
(1, 3, 6 months, and 12 months) will be included as the main predictors. Baseline composite 
score will be adjusted. A random intercept will be used to adjust for within-subject correlation. 
Time-specific (1, 3, 6, and 12 months) between-group differences will also be compared. 
 Similarly, MMRM will be used to compare groups on:  1) two secondary measures of 
overall improvement including the composite PROMIS pain-anxiety-depression score, and 
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patient-reported global improvement of pain and mood; 2) individual pain, anxiety, and 
depression scores (Aim 2); and 3) health-related quality of life, disability, and treatment 
satisfaction (Aim 3). To accommodate the large variability of health care utilization data, 
negative binomial distribution regression analysis will be used to model count data. For all 
secondary outcomes, the p-values will be adjusted for multiplicity using the Sidak method 
[56] where:  adjusted p-value = 1 – (1 – unadjusted p-value)# tests  Analyses will be performed 
using SAS Version 9.3. 
 Aim 4 will explore the independent effects of each of the 5 intervention components 
highlighted in the conceptual model (Figure 1). Analyses for this aim will include only CSM 
participants since they received all 5 active components. The 5 components will be quantified 
as follows:  1) automated monitoring contacts (total number); 2) self-management modules 
completed (range, 0 to 9); 3) medication changes (new analgesic and psychotropic starts 
and changes during the 12-month trial); 4) nurse contacts (total number); 5) mental health 
vis its (total number).  Linear regression models will be run for each of the 5 components (in 
separate models and together) with the 12-month change in PAD composite score as the 
dependent variable and the specific components as predictor variables. 
2.9. Qualitative interviews and analysis 
 A subsample of individuals completing their 12-month participation in the trial will be 
asked if they are interested in being interviewed about their experience with the CAMMPS 
intervention, and those willing to participate will complete written informed consent. 
Purposeful sampling will be used to include participants from both CSM and ASM arms as 
well as those who were improved vs. same or worse on patient-reported global rating of 
change. As with previous studies, we expect thematic saturation to occur after interviewing 
20 to 25 study participants [57,58]. An interview guide combining open-ended questions with 
a series of probing questions will be used to elicit perceived barriers and facilitators to key 
components of the interventions. Audio recordings of the 30 to 60 minute interviews will be 
transcribed, de-identified, and checked for accuracy. A team of analysts will use an 
immersion-crystallization approach to analyze the qualitative data. Discrepancies will be 
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resolved by consensus [59]. 
 
3. Results 
 Figure 4 shows the results of screening, eligibility determination, and enrollment, 
which was conducted from January 2014 through June 2016. Letters were mailed to 5596 
patients with an appropriate musculoskeletal pain or mental disorder ICD code of whom 1549 
expressed potential interest in the study by returning a letter or calling a study phone 
number. Of the 1176 patients who completed an eligibility interview, 397 met study eligibility 
criteria. The most common reasons for not being eligible were pain or depression/anxiety 
scores that were too low, or mental health problems that were too complex for a telecare 
intervention. Of the 397 eligible patients, 294 (74%) enrolled in the study and were 
randomized to the CSM (n = 147) or ASM (n = 147) arms of the trial. 
 Randomization resulted in comparable groups on all measured variables (Table 2) 
except one: probable PTSD was slightly more prevalent in the ASM arm although severity 
scores as measured by the PTSD checklist were similar between groups.  Overall, the 
sample had a mean age of 57.4 years (range, 25 to 88); 87.4% were men; 79.3% were 
white, 15.3% black, and 5.4% other race; 56.8% married; 27.9% were employed, 38.1% 
currently unemployed, and 34.0% retired; 21.1% were college graduates, 53.1% had some 
college or trade school, and 25.9% had only a high school diploma or GED. Income level 
was reported as “comfortable” by 39.2% of patients, “just enough to make ends meet” by 
41.2%, and “not enough to make ends meet” by 19.6%.  Diagnostic thresholds for probable 
major depressive disorder and probable PTSD were met by 162 (55.1%) and 163 (55.4%) of 
study participants, respectively. In terms of risk for substance use risk, 11.9% of patients 
were classified as high risk, 39.1% as intermediate risk, and 49.0% as low risk. 
 The mean baseline BPI total pain score was 5.9, with a mean BPI interference score 
of 6.1 and mean BPI severity score of 5.5, representing a moderate level of pain. The 
duration of pain was 3 to 12 months in 2.7% (n=8) of the patients, 1 to 5 years in 20.7% 
(n=61), 6 to 10 years in 19.4% (n=57), and more than 10 years in 57.1% (n=168). The 
median number of painful bodily s ites (from a checklist of 17 sites) was 5. Only 4.4% (n=13) 
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of the patients reported a s ingle site of pain, whereas 2 s ites were reported by 11.2% (n=33), 
3 s ites by 17.7% (n=52), 4 sites by 15.0% (n=44), 5 s ites by 13.6% (n=40), 6 s ites by 12.9% 
(n=38), 7 s ites by 9.2% (n=27), 8 to 9 s ites by 11.2% (n=33), and ≥ 10 sites by 4.8% (n=14). 
 
 
There were no significant differences between the intervention and usual care groups in 
terms of duration of pain or the number of pain sites. Patients reported that they had to cut 
down on their usual activities for one-half day or more on 15.4 days in the past 4 weeks, and 
work effectiveness was only 61%. Multiple domains of health-related quality of life were also 
substantially diminished. 
4. Discussion 
 CAMMPS successfully enrolled 294 primary care patients with chronic 
musculoskeletal pain and comorbid depression/anxiety, s lightly exceeding the enrollment 
goal of 286 participants.  Nearly three-fourths of eligible patients consented to participate, 
and randomization produced comparable intervention and control groups. The sample had 
moderately severe levels of pain as well as depression and anxiety, and major depression 
and posttraumatic stress disorder were each present in more than half of study participants. 
Self-reported disability was substantial, and there were major decrements in health-related 
quality of life.  
 CAMMPS focuses on patients with PAD comorbidity, i.e., those having pain plus 
anxiety and/or depression.  Whereas most previous studies have focused on the PAD 
symptoms individually, the high co-occurrence of these symptoms makes a mono-
symptomatic approach impractical as well as sub-optimally effective. Single-condition care 
management programs are not only costly but tend to provide fragmented disease-based 
care rather than integrated management of the complex patient with comorbidity. In 
particular, pain is viewed by clinicians and patients alike as primarily a “medical” condition, 
whereas depression and anxiety are considered “mental” disorders.  As a consequence, the 
management of pain and depression/anxiety too often gets carved up between the medical 
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and mental health components of the health care system, rather than being integrated and 
coordinated. 
 One limitation of CAMMPS is the exclusively Veteran sample that was predominantly 
white men who had a moderate degree of unemployment and financial constraints. 
Moreover, the focus on patients with both chronic pain and psychiatric comorbidity resulted in 
relatively high rates of self-reported disability and functional impairment. However, if 
CAMMPS proves effective, the results may provide a conservative estimate of benefits given 
the complex nature of both the patients’ disorders as well as life circumstances. A second 
limitation is the potential for selection bias arising from unmeasured differences between 
patients not responding to our mailed invitation and those we were able to contact by phone 
(Figure 4). On the other hand, enrollment rates were high among those we were able to 
contact and who met study eligibility criteria.  Third, the multicomponent nature of the 
CAMMPS intervention means that the specific effects of individual components will be 
difficult to unbundle from the overall effects of the intervention. However, this is true for many 
complex interventions for chronic disease [10, 60], and our proposed exploratory analyses 
may at least partly isolate the relative contributions of specific components. 
 In summary, CAMMPS compares a more resource-intensive intervention vs. a low-
resource, largely automated enhancement of usual care for the major symptom triad among 
Veterans in primary care. Innovations include an integrated approach to PAD symptom 
comorbidity rather than fragmented care of s ingle symptoms; coordinated symptom 
management in partnership with both primary care clinicians and psychologists embedded in 
primary care; the efficient use of health information technology; attention to physical and 
psychological symptom comorbidity; and the coupling of self-management with clinician-
administered pharmacological and behavioral treatments. Significance is heightened not only 
by a comparative test of CSM vs. ASM but also by their potential future use in a tailored or 
stepped care (rather than either-or) approach, their application to symptom management in 
specialty as well as primary care settings, and their relevance in augmenting symptom 
management provided by telecare services as well as patient-aligned care teams (PACTs) in 
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the VA or, in non-VA settings, patient-centered medical homes and accountable care 
organizations. 
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Table 1. CAMMPS Outcome Assessment:  Measures and Schedule of Administration 
 
Domain Measure 
# 
Items 
Alpha 
  Schedule (Month) 
0  1 3 6 12 
Primary PAD composite          
 Pain   Brief Pain Inventory 11 0.89 X X X X X 
 Anxiety  GAD-7 anxiety 7 0.79 X X X X X 
 Depression  PHQ-9 depression 9 0.73 X X X X X 
Secondary PAD composite          
 Pain  PROMIS pain 8 0.91 X  X X X 
 Anxiety  PROMIS anxiety 8 0.91 X  X X X 
 Depression  PROMIS depression 8 0.93 X  X X X 
Clinical response Global Rating of Change 2 n/a  X X X X 
Anxiety – secondary scales 
PTSD Checklist 17 0.91 X  X  X 
Mini-SPIN social anxiety 3 0.84 X     
HSCL anxiety  10 0.90 X  X  X 
Somatization 
PHQ-somatic  14 0.66 X    X 
SSS-8 8 0.72 X    X 
Health-related quality of life 
(Medical Outcomes Study 
Short-Form [SF] scales)  
SF-12 + 8 other SF items 20       
 Physical Component -- 0.85 X  X  X 
 Mental Component -- 0.85 X  X  X 
 SF-36 Social 
Functioning 
-- 0.86 X  X  X 
 SF-36 Bodily Pain -- 0.72 X  X  X 
 SF-36 Vitality -- 0.75 X  X  X 
 SF-36 Mental Health -- 0.79 X  X  X 
Disability 
Sheehan Disability Scale 3 0.85 X  X X X 
Disability days past 4 wks 2 n/a X  X X X 
Pain catastrophizing CSQ catastrophizing  6 0.87 X   X X 
Depression remission tool REMIT scale 5 0.76 X  X X X 
Fatigue PROMIS fatigue 4 0.90 X  X  X 
Sleep PROMIS sleep 4 0.77 X  X  X 
Sociodemographics 
age, race, sex, education, 
marital, job status, income 
7 n/a X     
Medical comorbidity Checklist of 9 diseases 9 n/a X     
Substance use 
alcohol, tobacco, illicit 
drugs 
13 n/a X     
Health care use 
Electronic medical 
records 
5 n/a     X 
Treatment for PAD  PAD-specific treatments 15 n/a X   X X 
Treatment satisfaction PAD-specific satisfaction 4 n/a   X  X 
Intervention satisfaction 
Automated monitoring 
and care management 
9 n/a     X 
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Table 2. Baseline Characteristics of 294 Subjects Enrolled in the CAMMPS Study  
Characteristic 
CSM Group 
(n = 147) 
ASM Group 
(n = 147) 
Age in years, mean (SD) 56.9 (12.5) 57.9 (11.7) 
Sex, % men 84.4 90.5 
Race, % white 78.9 79.6 
Education, % > high school 72.8 74.5 
Married, % 58.5 55.1 
Current smoker, % 27.2 24.5 
Major depression (probable), % 55.8 54.4 
Posttraumatic stress disorder (probable), %* 49.7 61.2 
Substance use risk intermediate to high, % 55.1 46.9 
Comorbid medical diseases, mean (SD) 2.3 (1.4) 2.3 (1.4) 
Pain scale scores [range], mean (SD) †   
   BPI pain total [0-10] 6.1 (2.0) 6.0 (1.9) 
   SF-36 pain [0-100] 29.3 (15.3) 29.8 (16.5) 
   PROMIS 8-item pain T-score [0-100; 50 = norm] 64.5   (5.5) 64.1   (5.9) 
   CSQ pain catastrophizing [0-36] 19.0 (8.8) 17.7 (9.2) 
Psychological scale scores [range], mean (SD) †   
   PHQ-9 depression [0-27] 14.4 (5.1) 13.7 (5.3) 
   GAD-7 anxiety [0-21] 11.3 (5.0) 11.1 (5.3) 
   PROMIS 8-item depression T-score [0-100; 50 = norm] 58.7 (8.0) 58.5 (8.7) 
   PROMIS 8-item anxiety T-score [0-100; 50 = norm] 61.2 (8.2) 60.8 (8.9) 
   SF-36 mental health [0-100] 51.9 (19.6) 52.7 (198) 
   Mini-SPIN social anxiety [0-12] 4.8 (3.9) 4.2 (3.7) 
   HSCL anxiety [0-4] 1.2 (0.8) 1.3 (1.0) 
   PTSD Checklist  [17-85] 44.1 (14.7) 45.5 (15.4) 
   REMIT depression remission score [0-20] 9.1 (3.8) 8.9 (3.8) 
   PHQ-14 somatization [0-28] 13.9 (3.9) 13.2 (4.2) 
   SSS-8 somatization [0-32] 17.1 (5.6) 16.3 (6.0) 
   AUDIT-C alcohol use [0-12] 2.2 (2.0) 2.7 (2.7) 
Health-related quality of life scores [range], mean (SD) †   
   SF-12 physical component summary [norm = 50] 33.2   (8.6) 33.2   (8.4) 
   SF-12 mental component summary [norm = 50] 37.5 (11.2) 38.2 (10.1) 
   SF-36 general health perceptions [0-100] 37.9 (27.0) 37.8 (29.0) 
   SF-36 social functioning [0-100] 43.3 (26.1) 43.6 (26.6) 
   SF-36 vitality [0-100] 27.6 (17.0) 27.5 (20.4) 
   PROMIS 4-item fatigue T-score [0-100; 50 = norm] 63.6   (8.2) 62.9   (8.3) 
   PROMIS 4-item sleep T-score [0-100; 50 = norm] 59.6   (7.6) 59.7   (7.8) 
Disability scores [range], mean (SD) †   
   Sheehan Disability Index [0-10] 5.7 (2.3) 5.7 (2.4) 
   Health-related disability days past 4 weeks [0-28] 15.7 (9.1) 15.2 (9.7) 
   Percent work effectiveness [0-100] 60.1 (25.2) 61.6 (28.0) 
* P = .047. There were no other s ignificant differences between intervention and usual care groups 
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† For scale scores, the range is the minimum to maximum possible score on the scale, and the   
   bolded number represents the worst score on the scale.  
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Legends 
 
 
Figure 1.  Conceptual model for CAMMPS trial, illustrating the 2 components of the 
automated symptom management (ASM) intervention and the 3 additional components 
of the comprehensive symptom management (CSM) intervention. Also, the primary 
outcome that the intervention is hypothesized to benefit is depicted as well as the 
secondary outcomes postulated to parallel improvements in the primary outcome. 
 
Figure 2.  Facilitated mental health care protocol for Comprehensive Symptom 
Management group. 
 
Figure 3.  Criteria-based algorithm for adjusting pain, anxiety and depression treatment. 
 
Figure 4.  Flow diagram of participant screening, eligibility and enrollment. A) Other 
reasons included living out of state (n=43), life expectancy less than 12 months (n=31), 
no VA primary care physician (n=29), deceased (n=23), cognitive impairment (n=20), 
severe visual or hearing impairment (n=12), pain less than 3 months (n=9), no 
analgesics tried (n=6), and other (n=8).  B) Indeterminate eligibility in 245 individuals 
who refused to do an eligibility interview and 128 who could not be contacted. 
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Criterion 3 
Treatment change desired by patient? 
Criterion 3 
Treatment change desired by patient? 
Response
? 
YES NO 
Probe reasons treatment 
change is desired 
Change 
treatment 
NO YES NO YES 
Figure 3.  Algorithm for Using Clinical Criteria to Decide on Treatment Changes  
 
Probe reasons treatment 
change is not desired 
Criterion Measure Partial response  
(4-11 weeks) 
Target response  
(≥ 12 weeks) 
1 
PEG (pain) 
PHQ-9 (depression) 
GAD-7 (anxiety) 
≥ 30% decrease 
≥ 50% decrease, or 
score of < 4 on PEG or  
< 5 on PHQ-9 or GAD-7 
2 Global improvement 4 or greater 
(“somewhat better”) 
6 or greater 
(“a lot better”) 
      Response =  both criteria met for ≥ 2 consecutive timepoints ≥ 2 weeks apart  
Continue same 
treatment 
treatment 
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Comprehensive vs. Automated Management 
of Mood and Pain Symptoms (CAMMPS) Trial 
5596 Letters Mailed 
1549  
Patient Expressed Initial Interest 
 
779 Ineligible for study 
       223  Low depression/anxiety score 
       159  Low pain score 
       211  Complex mental health history 
       181  Other reasons A 
373 Indeterminate eligibility B  
 
    
 
147 
Randomized to 
Comprehensive Symptom 
Management (CSM) 
4047  
Patient Did Not Express Interest 
 
 
 
397 
Eligible 
 
 
 
103 
Refused 
 
 
 
294 
Enrolled 
 
 
 
147 
Randomized to 
Automated Symptom 
Management (ASM) 
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